Literature DB >> 23080546

Analysis of the impact of PAPP-A, free β-hCG and nuchal translucency thickness on the advanced first trimester screening.

L Berktold1, C S von Kaisenberg, C V Kaisenberg, P Hillemanns, B Vaske, P Schmidt.   

Abstract

OBJECTIVES: The intention of this study is to analyze the impact of the single parameters NT, PAPP-A and free β-hCG used in combined first trimester screening and to determine their contribution in the risk assessment.
METHODS: A retrospective risk assessment on the advanced first trimester screening (AFS) algorithm was made to determine the effect of a particular parameter while the remaining ones were fixed for calculation. Afterward data were recalculated by the AFS module. Test performance was measured by receiver operating characteristics (ROC) curves and their area under curve (AUC).
RESULTS: Among the 14,862 cases are 14,748 healthy fetuses, 86 with trisomy 21, 22 with trisomy 18 and 6 with trisomy 13. Some settings obtain at default cut-off a very high sensitivity. However, a lack of specificity, as a high false-positive rate, too. The ROC analysis was best for NT, followed by PAPP-A. Free β-hCG showed the lowest AUC. Combining PAPP-A and free β-hCG offered a better AUC than each parameter alone. Best test performance was obtained by including all three parameters. DISCUSSION: A detection rate of 69 % for testing NT discretely is in order with present study data. PAPP-A is following and free β-hCG is not useful with a test positive rate of about a third. The detection rate of the biochemical parameters combined is higher than for NT alone, but results in a five times higher punctuation rate. All parameters together in the AFS provide the best test performance. The impact of each parameter NT, PAPP-A and free-β-hCG in a combined test strategy is nearly a third. Thus, every single parameter is needed to provide a high detection rate for all of the trisomies and minimize the number of unnecessary invasive diagnostics.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23080546     DOI: 10.1007/s00404-012-2585-y

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  5 in total

1.  The feasibility study of non-invasive fetal trisomy 18 and 21 detection with semiconductor sequencing platform.

Authors:  Young Joo Jeon; Yulin Zhou; Yihan Li; Qiwei Guo; Jinchun Chen; Shengmao Quan; Ahong Zhang; Hailing Zheng; Xingqiang Zhu; Jin Lin; Huan Xu; Ayang Wu; Sin-Gi Park; Byung Chul Kim; Hee Jae Joo; Hongliang Chen; Jong Bhak
Journal:  PLoS One       Date:  2014-10-20       Impact factor: 3.240

2.  Missed Down Syndrome Cases after First Trimester False-Negative Screening-Lessons to be Learned.

Authors:  Anca Angela Simionescu; Ana Maria Alexandra Stanescu
Journal:  Medicina (Kaunas)       Date:  2020-04-23       Impact factor: 2.430

3.  The Significance of Apolipoprotein E Measurement in the Screening of Fetal Down Syndrome.

Authors:  Angelika Buczyńska; Iwona Sidorkiewicz; Sławomir Ławicki; Adam Krętowski; Monika Zbucka-Krętowska
Journal:  J Clin Med       Date:  2020-12-10       Impact factor: 4.241

4.  Prenatal Screening of Trisomy 21: Could Oxidative Stress Markers Play a Role?

Authors:  Angelika Buczyńska; Iwona Sidorkiewicz; Sławomir Ławicki; Adam Jacek Krętowski; Monika Zbucka-Krętowska
Journal:  J Clin Med       Date:  2021-05-28       Impact factor: 4.241

Review 5.  Beyond Trisomy 21: Additional Chromosomal Anomalies Detected through Routine Aneuploidy Screening.

Authors:  Amy Metcalfe; Catriona Hippman; Melanie Pastuck; Jo-Ann Johnson
Journal:  J Clin Med       Date:  2014-04-08       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.